Which drug first? new trial aims to improve survival in tough colorectal cancer

NCT ID NCT04787341

Ongoing Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing two different sequences of the drugs panitumumab and regorafenib in 214 patients with advanced colorectal cancer that no longer responds to standard treatments. The goal is to see which order of these drugs helps patients live longer. Participants must have previously benefited from an anti-EGFR therapy and have no RAS or BRAF mutations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Panitumumab and regorafenib
What this could lead to: If successful, this trial could help determine the best order of these two drugs to extend survival in patients with advanced colorectal cancer who have run out of standard options.
What could go wrong: This is a phase 2 trial with only 214 participants, so results are not definitive. The drugs can cause side effects like skin reactions, fatigue, and liver issues, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

U.O. Oncologia 2 Universitaria

Pisa, PI, 56126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.